Aridis Pharmaceuticals
Aridis Pharmaceuticals
ARDS
OTC
0.00
USD
0.00%
About
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis.
The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501.
Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.5K |
| Three Month Average Volume | 1.5M |
| High Low | |
| Fifty-Two Week High | 0.124 USD |
| Fifty-Two Week Low | 0 USD |
| Fifty-Two Week High Date | 20 Sep 2023 |
| Fifty-Two Week Low Date | 28 Aug 2024 |
| Price and Volume | |
| Current Price | 0 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -5.34% |
| Thirteen Week Relative Price Change | -100.00% |
| Twenty-Six Week Relative Price Change | -100.00% |
| Fifty-Two Week Relative Price Change | -100.00% |
| Year-to-Date Relative Price Change | -100.00% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -100.00% |
| Twenty-Six Week Price Change | -100.00% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -100.00% |
| Year-to-Date Price Change | -100.00% |
| Month-to-Date Price Change | -99.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.89637 USD |
| Book Value Per Share (Most Recent Quarter) | -0.26477 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.897 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.26506 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 6.12004 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.16461 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.70744 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.61743 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.18453 USD |
| Normalized (Last Fiscal Year) | 10.47161 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.61743 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.17997 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.61743 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.18453 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.18037 USD |
| Cash Per Share (Most Recent Quarter) | 0.00079 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.59149 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.02636 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.56744 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,136 |
| Cash Flow Revenue (Trailing Twelve Months) | -80 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -5.11% |
| Pretax Margin (Last Fiscal Year) | -982.56% |
| Pretax Margin (5 Year) | -1,559.63% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -970.33% |
| Operating Margin (Trailing Twelve Months) | -3.95% |
| Operating Margin (5 Year) | -1,569.24% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -982.56% |
| Net Profit Margin (Trailing Twelve Months) | -5.11% |
| Net Profit Margin (5 Year) | -1,559.63% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 4.51% |
| Revenue Growth (3 Year) | 29.16% |
| Revenue Change (Trailing Twelve Months) | 680.42% |
| Revenue Per Share Growth | 8.60% |
| Revenue Growth (5 Year) | 44.62% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -34.84% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 99.52% |
| EPS Change (Trailing Twelve Months) | 90.46% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -35,000 |
| Net Debt (Last Fiscal Year) | -4,357,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | 0 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -29,209,000 |
| Free Cash Flow (Trailing Twelve Months) | -17,934,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 1.6K |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -146.40% |
| Return on Assets (Trailing Twelve Months) | -12.24% |
| Return on Assets (5 Year) | -120.16% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -678.29% |